2-Mercaptopyridine

2-Mercaptopyridine

SCHEMBL28679755

CC(S)c1ccc(C(=O)ON2C(=O)CCC2=O)cc1.Sc1ccccn1

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.35
MEN1 O00255 2/20 0.35
PKM P14618 2/20 0.35
MAPT P10636 3/20 0.34
POLB P06746 3/20 0.34
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 4/20 0.33
RAB9A P51151 4/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
GAA P10253 1/20 0.33
LMNA P02545 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
MAPK1 P28482 1/20 0.32
CYP2C19 P33261 1/20 0.32
HTT P42858 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
MGLL Q99685 2/20 0.32
KAT2B Q92831 3/20 0.32
CDK5 Q00535 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL322165 0.78 MAPT (0.40) KMT2AMEN1PKMMAPTPOLB
SCHEMBL42875 0.76 MAPT (0.36) KMT2AMEN1PKMMAPTPOLB
SCHEMBL29386113 0.76 MAPT (0.36) KMT2AMEN1PKMMAPTPOLB
SCHEMBL29592639 0.75 KMT2A (0.33) KMT2AMEN1PKMMAPTPOLB
SCHEMBL12727641 0.75 POLB (0.49) KMT2AMEN1POLBNPC1RAB9A
SCHEMBL992708 0.72 KMT2A (0.56) KMT2AMEN1PKMMAPTPOLB
SCHEMBL300884 0.71 CA12 (0.42) KMT2AMEN1MAPTKDM4ERAB9A
2-Mercaptopyridine SCHEMBL28724071 0.71 SMN1; SMN2 (0.39) KMT2AMEN1KDM4ESMN1; SMN2LMNA
SCHEMBL10070313 0.70 ALDH1A1 (0.37) KMT2AMEN1MAPTKDM4ENPC1
SCHEMBL19309377 0.70 KMT2A (0.53) KMT2AMAPTPOLBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115340607-A anti-CD 166 antibodies, activatable anti-CD 166 antibodies, and methods of use thereof 西托姆克斯治疗公司 2022-11-15 CN disclosed
CN-107849133-B anti-CD 166 antibodies, activatable anti-CD 166 antibodies, and methods of use thereof 西托姆克斯治疗公司 2022-08-23 CN disclosed
CN-114907446-A Matrix metalloprotease cleavable and serine protease cleavable substrates and methods of use thereof 西托姆克斯治疗公司 2022-08-16 CN disclosed
CN-114716513-A Matrix metalloprotease cleavable and serine protease cleavable substrates and methods of use thereof 西托姆克斯治疗公司 2022-07-08 CN disclosed
CN-114685611-A Matrix metalloprotease cleavable and serine protease cleavable substrates and methods of use thereof 西托姆克斯治疗公司 2022-07-01 CN disclosed
CN-114685661-A Matrix metalloprotease cleavable and serine protease cleavable substrates and methods of use thereof 西托姆克斯治疗公司 2022-07-01 CN disclosed
CN-114591433-A anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use thereof 西托姆克斯治疗公司 2022-06-07 CN disclosed
CN-114507283-A anti-CD 71 antibodies, activatable anti-CD 71 antibodies, and methods of use thereof 西托姆克斯治疗公司 2022-05-17 CN disclosed
CN-114478704-A Matrix metalloprotease cleavable and serine protease cleavable substrates and methods of use thereof 西托姆克斯治疗公司 2022-05-13 CN disclosed
CN-108368170-B anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use thereof 西托姆克斯治疗公司 2022-04-15 CN disclosed
CN-108026170-B anti-CD 71 antibodies, activatable anti-CD 71 antibodies, and methods of use thereof 西托姆克斯治疗公司 2022-03-01 CN disclosed
CN-107531758-B Matrix metalloprotease cleavable and serine protease cleavable substrates and methods of use thereof 西托姆克斯治疗公司 2022-02-11 CN disclosed